Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 671055
                    [Title] => Roche announces positive results for severe skin cancer medicine
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
                    [DatePublished] => 2011-03-31 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

HEDGEHOG PATHWAY INHIBITOR

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 671055
                    [Title] => Roche announces positive results for severe skin cancer medicine
                    [Summary] => 
BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.
                    [DatePublished] => 2011-03-31 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche announces positive results for severe skin cancer medicine

March 31, 2011 - 12:00am

BASEL, Switzerland — Roche announced this week that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib, showed positive results in people with advanced basal cell...

Science and Environment